Regulatory updates (higher clinical relevance)
New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …
WHY IT MATTERS: As federal rescheduling moves forward, organizations that center both clinical evidence and patient experience could directly shape whether patients gain broader, safer, and more affordable access to cannabinoid therapies. CLINICAL OVERVIEW: A newly formed cannabis medicine group is working to ensure that federal policy discussions around cannabinoid therapy are rooted in scientific evidence and shaped by real patient perspectives. This effort comes at a critical moment as rescheduling conversations advance at the federal level, creating an opening to influence how cannabis is regulated, researched, and integrated into clinical care.
Medical and recreational marijuana bills introduced in Kansas Legislature – KAKE
WHY IT MATTERS: If Kansas passes medical cannabis legislation, patients currently traveling to neighboring states or going without treatment may soon be able to access cannabis-based therapies legally and closer to home. CLINICAL OVERVIEW: Kansas is considering legislation that would establish both medical and recreational cannabis frameworks, representing a significant shift for one of the few remaining states with no legal cannabis access. The medical proposals include pathways for patients with qualifying conditions to access cannabis-based treatments under physician supervision, while rescheduling efforts at the federal level have created new momentum for states like Kansas to act.
5 Transformative Effects of Cannabis Rescheduling: Medical Insight
In a recent landmark announcement on Cannabis Rescheduling, President Biden expressed his administration's commitment to support the rescheduling of cannabis from Schedule 1 to Schedule 3 of the Controlled Substances Act. This...